Study S001155

Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04046822
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: UNKNOWN
Enrollment: 70
Start: 2019-01-09
Primary completion: 2020-01-09
Lead sponsor: Federico II University
Conditions: Obesity; Weight Loss; Microbiome
Interventions: DRUG:Liraglutide 6 MG/ML [Saxenda]; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in gut microbiome composition assessed by Firmicutes-to-Bacteroidetes ratio using Quantitative polymerase chain reaction (PCR) [Change from baseline in gut microbiome composition at weeks 5 (visit 7)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013369	Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Nakatani Y, Diabetes & metabolism	2017	Nonrandomized study	PMID 28648835 DOI	registry reference BACKGROUND:28648835